Clinical trials: Anthracycline-induced Cardiotoxicity
Lymphoma, Large B-Cell
Study Investigating the Cardiotoxicity of Anthracyclines in Patients With Diffuse Large B-Cell
All patients enrolled in the study will have to be treated with a chemo immunotherapy scheme R-CHOP with doxorubicin, with doxorubicin analogue or non pegylated liposomal anthracycline (R-COMP; Sec.
- Conditions
- Lymphoma, Large B-Cell, Diffuse Large B-Cell
- Trial name
- NCT02916316
- Testing
- R-CHOP with doxorubicin
- Where
- 18 sites in Italy
- Volunteers
- 127 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Breast Cancer, Cardiotoxicity
Cardiotoxicity Prevention in Breast Cancer Patients Treated With Anthracyclines and/or Trastuzumab
The aim of the study is to analyze the protective impact on the cardiac damage of beta blockers and ACE inhibitors for breast cancer patients treated with anthracyclines-based chemotherapy with or without trastuzumab.
- Trial name
- SAFE (NCT02236806)
- Testing
- Bisoprolol, Ramipril
- Where
- Italy
- Volunteers
- 262 people
- Sponsor
- Azienda Ospedaliero-Universitaria Careggi
Neoplasms
Low-dose CT-based Method for Detection of Subclinical Anthracycline-induced Cardiotoxicity
Prospective single arm study to evaluate a low-dose CT-based protocol for early detection of myocardial dysfunction in 50 cancer patients undergoing anthracycline-based chemotherapy.
- Trial name
- NCT03553654
- Testing
- low dose CT
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of California, San Diego
Wilms Tumor, Neuroblastoma
Pharmacokinetic Study of Doxorubicin in Children With Cancer
Analyze pharmacokinetics of doxorubicin in children with cancer. Furthermore investigate the predictive role of troponin and natriuretic peptides for anthracycline-induced cardiotoxicity .
- Conditions
- Wilms Tumor, Neuroblastoma, Soft Tissue Sarcoma, Acute Lymphoblastic Leukemia
- Trial name
- Doxo (NCT01095926)
- Testing
- doxorubicin
- Where
- 23 sites in France, Germany and 2 more
- Volunteers
- 101 people
- Sponsor
- University Hospital Muenster
Cardiotoxicity Induced by Drug Therapy for Breast Cancer
The Use of Shengmai San to Prevent Anthracycline Sequential Trastuzumab Therapy Related Cardiac Toxicity
To evaluate the effectiveness and safety of Shengmai San in preventing anthracycline sequential trastuzumab therapy related cardiac toxicity through a prospective randomized controlled study.
- Trial name
- START (NCT06214195)
- Testing
- Shengmai San (ingredients include ginseng, Ophiopogon japonicus, and Schisandra chinensis)
- Where
- China
- Volunteers
- 276 people
- Sponsor
- Zhejiang Cancer Hospital
Breast Cancer
Potential Protective Role of SGLT-2 Inhibitors for Chemotherapy-induced Cardiotoxicity
The purpose of this study is to evaluate whether dapagliflozin reduces chemotherapy-induced cardiotoxicity in participants with breast cancer treated with (neo-)adjuvant Anthracycline-based chemotherapy +/- trastuzumab.
- Trial name
- PROTECT (NCT06341842)
- Testing
- Dapagliflozin 10mg Tab
- Where
- Italy
- Volunteers
- 316 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Cardiotoxicity, Cardiac Rehabilitation
Exercise-based Cardiac Rehabilitation for the Prevention of Breast Cancer Chemotherapy-induced Cardiotoxicity
This project aims to determine whether a comprehensive cardiac rehabilitation program including supervised exercise training is able to prevent cardiotoxicity during treatment with anthracyclines and / or anti-HER-2 antibodies in…
- Trial name
- ONCORE (NCT03964142)
- Testing
- Cardiac rehabilitation
- Where
- Spain
- Volunteers
- 122 people
- Sponsor
- Hospital Clinico Universitario de Santiago
Breast Cancer
Cardiotoxicity of Cancer Therapy (CCT)
The objective of this study is to define the clinical significance of mechanistic biomarkers (including Neuregulin-1Beta) and novel echocardiographic measures of cardiac function in predicting the incident risk of cancer therapy…
- Trial name
- NCT01173341
- Testing
- Echocardiography, Blood Collection, Symptoms Questionnaire
- Where
- United States
- Volunteers
- 700 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Cardiotoxicity, Anthracycline Related Cardiotoxicity in Breast Cancer
ANTthracycline-induced Inflammation and OXidative Stress: 10-year Follow-up
The goal of this observational study is to learn about the long-term effects of anthracycline chemotherapy on inflammation, oxidative stress, and heart function in adult women with breast cancer.
- Conditions
- Cardiotoxicity, Anthracycline Related Cardiotoxicity in Breast Cancer, Breast Cancer
- Trial name
- ANTIOX-10 (NCT07680855)
- Volunteers
- 17 people
- Sponsor
- University of Chile
Cardiotoxicity, Heart Failure
ML Score Prediction of Cardiotoxicity in Cancer Patients Receiving Anthracycline Chemotherapy or HER2-Targeted Therapies
Cancer treatments have improved substantially over the past decades, but some effective therapies such as anthracyclines and HER2-targeted agents are associated with severe cardiovascular adverse effects, including heart failure.
- Conditions
- Cardiotoxicity, Heart Failure, Neoplasms, Breast Neoplasms
- Trial name
- ML-CardioTox (NCT07191730)
- Where
- France
- Volunteers
- 600 people
- Sponsor
- University Hospital, Caen
Cardiomyopathy Due to Drug
Myocardial Fibrosis Identification in Patients With Anthracycline-induced Cardiotoxicity
This is an interventional study for patients who had developed Anthracycline-Induced Cardiotoxicity (AIC) during or after anthracycline-containing therapy, referred to the Cardioncology Unit for heart failure treatment
- Trial name
- NCT06331806
- Testing
- Evaluation of myocardial fibrosis
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- European Institute of Oncology
Cardiotoxicity, Breast Cancer
Identification of Novel Inflammation-related Biomarkers for Early Detection of Anthracycline-induced Cardiotoxicity in Breast Cancer Patients
This study aims to identify possible set of inflammatory biomarkers before, during and after anthracycline-based chemotherapy in breast cancer patients to identify (sub)clinical chemotherapy-related cardiac dysfunctionCRCD to…
- Conditions
- Cardiotoxicity, Breast Cancer, Heart Failure
- Trial name
- NCT05298072
- Volunteers
- 180 people
- Sponsor
- University Hospital, Essen
Cancer, Breast, Cardiotoxicity
Exercise to Prevent AnthraCycline-based Cardio-Toxicity Study 2.0 (EXACT2)
Although great progress has been made in treating breast cancer, long-term health may be impaired by cancer therapy. For example, some chemotherapy drugs (e.g., anthracyclines) are known to cause declines in heart health.
- Conditions
- Cancer, Breast, Cardiotoxicity, Cardiovascular Diseases
- Trial name
- EXACT2 (NCT03748550)
- Testing
- Aerobic exercise
- Where
- 2 sites in Canada
- Volunteers
- 7 people
- Sponsor
- Nova Scotia Health Authority
Leukemia, Cardiac Toxicity
Early Detection of Anthracycline Cardiotoxicity by Echocardiographic Analysis of Myocardial Deformation in 2D Strain
It is now accepted that the anticancer properties of anthracyclines were allowed in many malignancies improve the prognosis of affected populations.
- Trial name
- CA2D (NCT01212926)
- Testing
- Echographic analysis of myocardial deformation in 2D strain
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Bordeaux
Doxorubicin Induced Cardiomyopathy
Role of Statin Therapy in Prevention of Anthracycline-Induced Cardiotoxicity
This study aims at evaluating the role of Atorvastatin in prevention of Anthracycline induced cardiotoxicity
- Trial name
- NCT05792293
- Testing
- Atorvastatin 40 Mg Oral Tablet
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Ain Shams University
Breast Cancer
Assessment of Cardiotoxicity After Chemotherapy for Breast Cancer by Cardio-vascular Magnetic Resonance (MR)
Consecutive patients with a first diagnosis of breast cancer will be identified at the Tom Baker Cancer Centre (TBCC) and included into the study, if they are going to receive chemotherapy with anthracyclines and / or Trastuzumab…
- Trial name
- Cardiotox (NCT00679874)
- Testing
- Cardio-vascular MRI
- Where
- Canada
- Volunteers
- 66 people
- Sponsor
- University of Calgary
Cardiotoxicity, Breast Cancer
Dietary Restriction to Prevent Cardiotoxicity in Breast Cancer Patients
The goal of this clinical trial is to compare a dietary intervention with a regular diet in patients with early breast cancer undergoing anthracycline based chemotherapy.
- Trial name
- PROTECT-COR (NCT06622954)
- Testing
- Protein- and Calorie restriction
- Where
- Netherlands
- Volunteers
- 32 people
- Sponsor
- Erasmus Medical Center
Cardiotoxicity
Effect of Remote Ischaemic Conditioning in Oncology Patients
Cancer survival has improved steadily due to earlier detection and treatment. Despite the established efficacy of anthracycline chemotherapy, its damaging effects on the heart (cardiotoxicity) limits treatment and confers acute…
- Trial name
- ERIC-ONC (NCT02471885)
- Testing
- Remote Ischaemic Conditioning
- Where
- United Kingdom
- Volunteers
- 128 people
- Sponsor
- University College, London
Breast Neoplasm Female, Lymphoma
Cancer Adverse Effects PReventIon With Care & Exercise: the CAPRICE Study
Breast cancer is the most common cancer among women worldwide. Similarly, Hodgkin and non- Hodgkin lymphomas make up two of the most prevalent cancers in men and women.
- Conditions
- Breast Neoplasm Female, Lymphoma, Cardiotoxicity, Anthracyclines
- Trial name
- NCT03850171
- Testing
- Exercise Training
- Where
- 4 sites in Switzerland
- Volunteers
- 57 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Cancer, Cardiotoxicity
Role of Aerobic Exercise to Modulate Cardiotoxicity in Long Term Cancer Survivors Exposed to Anthracycline Therapy
Over 50% of the more than 270,000 childhood cancer survivors in the U.S. have been treated with anthracyclines and thus are at risk of developing cardiotoxicity.
- Trial name
- NCT04036032
- Testing
- Exercise program
- Where
- 2 sites in United States
- Volunteers
- 47 people
- Sponsor
- Connecticut Children's Medical Center